New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 16, 2014
06:56 EDTMXIM, EWP, CRAY, A, HUM, SFLHigh option volume stocks: SFL A EWP HUM CRAY MXIM
News For SFL;A;EWP;HUM;CRAY;MXIM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 18, 2015
11:04 EDTMXIMMaxim Integrated says will continue to see consolidation in the industry
Subscribe for More Information
11:00 EDTMXIMMaxim Integrated says goal for automotive gross margins is low 60s
Subscribe for More Information
May 15, 2015
12:04 EDTMXIMThird Point reports new stakes in Maxim Integrated, NXP Semiconductors
Subscribe for More Information
11:08 EDTHUMOmega Advisors gives quarterly update on stakes
NEW STAKES: Targa Resources (TRGP), Targa Resources Partners (NGLS), Humana (HUM), Dow Chemical (DOW), and Twenty-First Century Fox (FOXA). INCREASED STAKES: Kinder Morgan (KMI), Chimera Investment Corporation (CIM), AerCap Holdings (AER), Shire (SHPG), and KKR & Co. (KKR). DECREASED STAKES: eBay (EBAY), Altisource Portfolio Solutions (ASPS), Caesars Entertainment (CZR), Navient (NAVI), and TerraForm Power (TERP). LIQUIDATED STAKES: HCA Holdings (HCA), Gilead (GILD), Cabot Oil & Gas (COG), and Apple (AAPL).
10:34 EDTMXIMOptions with increasing implied volatility
Subscribe for More Information
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
May 14, 2015
15:44 EDTMXIMMaxim Integrated calls active on report Avago interested in potential takeover
Subscribe for More Information
15:37 EDTMXIMAvago could spend $10B on takeover, eyeing Xilinx, Maxim, Reuters says
Subscribe for More Information
15:31 EDTMXIMXilinx jumps 5% after Reuters says Avago interested in potential takeover
Maxim Integrated (MXIM) rose 5% as well after it was also reported by Reuters to be a potential target for Avago (AVGO).
15:29 EDTMXIMAvago interested in potential deal for Xilinx, Maxim Integrated, Reuters says
Subscribe for More Information
May 13, 2015
11:22 EDTHUMOptions with increasing implied volatility
Subscribe for More Information
10:18 EDTHUMAnalyst says sell Humana amid 'wishful' takeover speculation
Subscribe for More Information
10:01 EDTHUMOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:08 EDTAAgilent volatility elevated into Q1 and sales outlook
Subscribe for More Information
06:12 EDTHUMHumana downgraded to Underperform from Neutral at Sterne Agee CRT
Sterne Agee CRT analyst Brian Wright downgraded Humana (HUM) to Underperform saying speculation about a takeover is "wishful thinking" at current share levels. The stock rallied 4% yesterday after Leerink told investors that Aetna (AET) may acquire Humana or Cigna (CI) in the near-term. Wright also sees "material" risk to Humana's earnings guidance risk with paid claims outpacing premium growth. He lowered his price target for shares to $150 from $165. Humana shares closed yesterday up $6.76 to $173.38.
May 12, 2015
15:46 EDTHUMHumana May volatility increases on sharp rally
Subscribe for More Information
11:53 EDTHUMAnalyst predicts large transaction 'imminent' for Aetna
Subscribe for More Information
10:28 EDTHUMOptions with increasing implied volatility: YELP HUM LULU CTRX
Subscribe for More Information
10:04 EDTHUMHigh option volume stocks
Subscribe for More Information
09:53 EDTHUMAetna merger with Cigna or Humana likely 'imminent,' says Leerink
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use